The severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) global pandemic is a devastating event that is causing thousands of victims every day around the world. One of the main reasons of the great impact of coronavirus disease 2019 (COVID-19) on society is its unexpected spread, which has not allowed an adequate preparation. The scientific community is fighting against time for the production of a vaccine, but it is difficult to place a safe and effective product on the market as fast as the virus is spreading. Similarly, for drugs that can directly interfere with viral pathways, their production times are long, despite the great efforts made. For these reasons, we analyzed the possible role of non-pharmacological substances such as supplements, probiotics, and nutraceuticals in reducing the risk of Sars-CoV-2 infection or mitigating the symptoms of COVID-19. These substances could have numerous advantages in the current circumstances, are generally easily available, and have negligible side effects if administered at the already used and tested dosages. Large scientific evidence supports the benefits that some bacterial and molecular products may exert on the immune response to respiratory viruses. These could also have a regulatory role in systemic inflammation or endothelial damage, which are two crucial aspects of COVID-19. However, there are no specific data available, and rigorous clinical trials should be conducted to confirm the putative benefits of diet supplementation, probiotics, and nutraceuticals in the current pandemic.

Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection. A scoping review / Infusino, F.; Marazzato, M.; Mancone, M.; Fedele, F.; Mastroianni, C. M.; Severino, P.; Ceccarelli, G.; Santinelli, L.; Cavarretta, E.; Marullo, A. G. M.; Miraldi, F.; Carnevale, R.; Nocella, C.; Biondi-Zoccai, G.; Pagnini, C.; Schiavon, S.; Pugliese, F.; Frati, G.; D'Ettorre, G.. - In: NUTRIENTS. - ISSN 2072-6643. - 12:6(2020), pp. 1-21.

Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection. A scoping review

Infusino F.
;
Marazzato M.;Mancone M.;Fedele F.;Mastroianni C. M.;Severino P.;Ceccarelli G.;Santinelli L.;Cavarretta E.;Marullo A. G. M.;Miraldi F.;Carnevale R.;Nocella C.;Biondi-Zoccai G.;Pagnini C.;Schiavon S.;Pugliese F.;Frati G.;D'Ettorre G.
2020

Abstract

The severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) global pandemic is a devastating event that is causing thousands of victims every day around the world. One of the main reasons of the great impact of coronavirus disease 2019 (COVID-19) on society is its unexpected spread, which has not allowed an adequate preparation. The scientific community is fighting against time for the production of a vaccine, but it is difficult to place a safe and effective product on the market as fast as the virus is spreading. Similarly, for drugs that can directly interfere with viral pathways, their production times are long, despite the great efforts made. For these reasons, we analyzed the possible role of non-pharmacological substances such as supplements, probiotics, and nutraceuticals in reducing the risk of Sars-CoV-2 infection or mitigating the symptoms of COVID-19. These substances could have numerous advantages in the current circumstances, are generally easily available, and have negligible side effects if administered at the already used and tested dosages. Large scientific evidence supports the benefits that some bacterial and molecular products may exert on the immune response to respiratory viruses. These could also have a regulatory role in systemic inflammation or endothelial damage, which are two crucial aspects of COVID-19. However, there are no specific data available, and rigorous clinical trials should be conducted to confirm the putative benefits of diet supplementation, probiotics, and nutraceuticals in the current pandemic.
File allegati a questo prodotto
File Dimensione Formato  
Infusino_Diet Supplementation_2020.pdf

accesso aperto

Note: https://www.mdpi.com/2072-6643/12/6/1718
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 410.9 kB
Formato Adobe PDF
410.9 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1416901
Citazioni
  • ???jsp.display-item.citation.pmc??? 79
  • Scopus 107
  • ???jsp.display-item.citation.isi??? 87
social impact